Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 466.85M P/E - EPS this Y 71.90% Ern Qtrly Grth -
Income -30.01M Forward P/E -6.59 EPS next Y -172.20% 50D Avg Chg -10.00%
Sales - PEG -0.31 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 3.41 EPS next 5Y 73.70% 52W High Chg -33.00%
Recommedations 1.40 Quick Ratio 3.83 Shares Outstanding 59.41M 52W Low Chg 61.00%
Insider Own 2.49% ROA -14.29% Shares Float 43.18M Beta 1.45
Inst Own 61.28% ROE -23.94% Shares Shorted/Prior 2.71M/2.43M Price 7.97
Gross Margin - Profit Margin - Avg. Volume 1,220,874 Target Price 9.25
Oper. Margin - Earnings Date Aug 1 Volume 486,154 Change -0.38%
About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc. News
06/20/24 Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
06/14/24 Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
06/13/24 Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
06/12/24 Aldeyra Therapeutics to Host Investor Roundtable Q&A
05/29/24 Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
05/14/24 Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
05/08/24 Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
04/25/24 Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
04/22/24 Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
04/18/24 Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
04/06/24 Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
04/05/24 Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
04/03/24 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner
03/28/24 Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
03/13/24 Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
03/06/24 Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
03/04/24 Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
03/01/24 Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
02/29/24 5 Small Drug Stocks to Buy From a Rebounding Industry
02/22/24 Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company
ALDX Chatroom

User Image MontanaT Posted - 7 hours ago

$ALDX Strong..$10 is a given..not about the battles Let’s win the war. Long time coming.. GLTA LFG!! Stoked!!! Shit can gap up crazy…

User Image Dfw_Birdman Posted - 12 hours ago

$ALDX after hours

User Image MontanaT Posted - 13 hours ago

$ALDX gonna get realllly interesting these coming weeks😆😁

User Image User123321 Posted - 18 hours ago

$ALDX Lots of biotechs behaving well and close to breakouts or false break outs. Great data would be welcome right about now. 😀👍

User Image GoldmanSlaps Posted - 18 hours ago

$ALDX shes brewing

User Image Kingjake26 Posted - 20 hours ago

$ALDX Shouldn’t we have results by now? I figured we would have them now

User Image Dfw_Birdman Posted - 1 day ago

$ALDX tomorrow up 37%

User Image RoyBaschMD Posted - 1 day ago

$ALDX

User Image Dfw_Birdman Posted - 1 day ago

$ALDX tomorrow is Friday, do you still think this is happening?

User Image Kingjake26 Posted - 1 day ago

$ALDX good day

User Image MontanaT Posted - 1 day ago

$ALDX

User Image TagyouRit Posted - 1 day ago

$ALDX SPA on clinical trial due soon

User Image Texout Posted - 1 day ago

$ALDX abbv posting ok results with slight beat. They better say they have nice pipeline coming through in the eye space on that earnings call ;-) otherwise tough to get excited

User Image Dfw_Birdman Posted - 2 days ago

$ALDX whoever that birdie guy/gal is.. they/them/he/him/her/she/it must know something!

User Image SocioCobb Posted - 2 days ago

$ALDX Ye 'ol C&H 👀

User Image Dfw_Birdman Posted - 2 days ago

$ALDX I think he’s going to be right. $5 by frEYEday

User Image Dfw_Birdman Posted - 2 days ago

$ALDX very true, Bird!

User Image mmtiddy Posted - 2 days ago

$ALDX chirp chirp

User Image Texout Posted - 2 days ago

@johnnygogogo $ALDX should go well in my view as mentioned before also a) the CRL was technical and related to the co primary sign endpoint, nasal staining. b) current trial is targeting discomfort as primary endpoints where a near identical trial in 2022 showed P <0.0001 values, to me the risk reward is skewed to the upside.

User Image johnnygogogo Posted - 2 days ago

$ALDX can we start a real discussion here amongst real shareholders? Who thinks Reprox readout will go the right way (or wrong way) and why?

User Image johnnygogogo Posted - 2 days ago

$ALDX hey Birdman of Alcanothing, why do you keep “liking” your own posts? I think you have a short position, tbh.

User Image Dfw_Birdman Posted - 2 days ago

$ALDX market down big but no sellers here. People know the bird knows….

User Image Dfw_Birdman Posted - 2 days ago

$ALDX just spoke with Todd. Soon.

User Image rahmanoof Posted - 2 days ago

$ALDX once ph3 R data is out , no one will wait for NDA , it will sky rocket 😉

User Image HenryDotDotDot Posted - 3 days ago

$ALDX I've been adding every day since I sold MCRB, will continue to add for the rest of the week.

User Image TampaTony Posted - 3 days ago

$ALDX blocked 'em.

User Image Dfw_Birdman Posted - 3 days ago

$ALDX next month a #2 at Apple Jacks’ favorite spot- McDonald’s- will be cheaper than a share of ALDX.

User Image RoyBaschMD Posted - 3 days ago

$ALDX

User Image TagyouRit Posted - 3 days ago

$ALDX very

User Image johnnygogogo Posted - 3 days ago

$ALDX Stfu_Birdman

Analyst Ratings
Oppenheimer Outperform May 6, 24
HC Wainwright & Co. Buy May 6, 24
Oppenheimer Outperform Apr 3, 24
Citigroup Buy Oct 17, 23
Oppenheimer Perform Oct 17, 23
Oppenheimer Outperform Aug 9, 23
HC Wainwright & Co. Buy Jun 30, 23
HC Wainwright & Co. Buy Jun 22, 23
HC Wainwright & Co. Buy Jun 16, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Oct 16 Sell 1.67 2,756,499 4,603,353 8,593,586 10/18/23
Brady Todd C President and CEO President and CEO Sep 07 Option 0.55 273,058 150,182 1,728,343 09/11/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 08 Buy 7.24 97,000 702,280 11,235,085 08/10/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 04 Buy 6.17 95,100 586,767 10,997,085 08/08/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 01 Buy 5.05 144,185 728,134 10,389,579 08/03/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Jul 28 Buy 5.00 119,392 596,960 10,023,271 08/01/22
JOYCE MARTIN JOSEPH Director Director Jun 23 Buy 3.4755 4,323 15,025 23,967 06/27/22
Brady Todd C President and CEO President and CEO Jun 23 Buy 3.3642 17,700 59,546 1,216,535 06/27/22
- - - Jan 11 Buy 8.79 1,050,000 9,229,500 7,335,458 01/11/21